The 2026 Bundibugyo Ebola Outbreak in the DRC: A Crisis Without a Vaccine

Geographic Spread

The epidemic is concentrated in the northeastern DRC.

• Epicenter: Ituri Province, particularly the health zones of Rwampara, Mongbwalu, and Bunia .
• Provincial spread: Cases have been confirmed in North Kivu and South Kivu provinces .
• Kisangani: Contrary to some concerns, no cases have been documented in Kisangani (Tshopo Province) in the available source set.
• Uganda: 20 confirmed cases; 15 had travel links to the DRC, and 5 resulted from local transmission . Uganda closed its border with the DRC in early June .

International Cases

• United States: No cases confirmed; the CDC assesses the risk to the U.S. public as low .
• EU/EEA: No cases reported; the ECDC assesses the risk to the general European population as "very low" .
• Other countries: No confirmed exported cases beyond Uganda and the DRC have been reported.

Economic Impact

The economic consequences are severe and escalating.

• UNDP projection (June 30, 2026): The outbreak could cost Africa up to $3.6 billion and hundreds of thousands of jobs. A "best-case" contained scenario estimates $1 billion in losses; a worst-case scenario involving spread to countries like Rwanda and Angola, combined with higher fuel costs, could reach $3.6 billion and eliminate 328,000 jobs .
• Scenario modeling (Institute for Security Studies): A "delayed-containment" scenario projects high economic costs through reduced productivity, disrupted trade and investment, and increased fiscal burdens .
• Local impact: Bunia, the capital of Ituri, faces severe supply shortages and economic disruption. The outbreak compounds existing damage from ongoing armed conflict and U.S. aid cuts, which weakened public health programs before the outbreak .
• Travel and trade: Border closures between Uganda and the DRC, reduced transport, and diminished tourism are amplifying regional economic damage .
• Food insecurity: The WFP reports that 26.5 million people in the DRC were already acutely food insecure before the outbreak; movement restrictions and market closures are worsening the situation .

Key Response Challenges

1. No Approved Vaccines or Treatments for Bundibugyo

This is the single most critical biomedical challenge.

• No licensed vaccine exists for the Bundibugyo strain. Existing Ebola vaccines (e.g., Ervebo) protect only against Zaire ebolavirus .
• No approved antiviral treatments are available. The two licensed monoclonal antibody therapeutics (Inmazeb and Ebanga) are Zaire-specific and ineffective against Bundibugyo . Treatment is limited to supportive care—rehydration, electrolyte management, and stabilization of oxygen and blood pressure .
• Diagnostics gap: GeneXpert, the most commonly used frontline diagnostic tool, detects Zaire ebolavirus but not Bundibugyo, substantially delaying case confirmation and isolation .
• Mortality rate: Bundibugyo has a case fatality rate reaching up to 40% .

International health experts met in mid-May to urgently explore vaccine candidates , and the WHO convened experts on May 28 to recommend candidate treatments for evaluation, including the monoclonal antibodies MBP134 and Maftivimab, and the antiviral remdesivir . However, no authorized product has yet been deployed for this strain.

2. Conflict and Security

The outbreak is unfolding in a region already destabilized by armed conflict. More than 130 armed groups operate in parts of Ituri and the Kivus, hindering surveillance, treatment access, and safe burials .

3. Community Mistrust

WHO Director-General Tedros Adhanom Ghebreyesus has described community mistrust as a "major barrier" to ending the outbreak , complicating contact tracing and treatment acceptance .

4. Weak Health Infrastructure

Poor healthcare infrastructure in eastern DRC, compounded by cuts to U.S.-backed public health programs, has weakened the region's ability to detect and contain the virus . The International Rescue Committee reported that its programming was reduced from five health areas in Ituri to just two following funding cuts .

5. Rapid Escalation and WHO PHEIC

On May 17, 2026, the WHO Director-General declared the outbreak a Public Health Emergency of International Concern (PHEIC)—the highest alert level—reflecting the speed of spread and the unique risk posed by an untreatable, unvaccinated strain .

Bottom Line

The Bundibugyo outbreak is the third-largest Ebola epidemic on record, escalating from roughly 400 to over 1,460 confirmed cases in one month and spreading across three DRC provinces and into Uganda. No international cases beyond Uganda have been confirmed. The total absence of any approved vaccine or treatment for this strain—compounded by conflict, infrastructure gaps, funding shortfalls, and community mistrust—makes this one of the most difficult Ebola responses in history. The UN projects potential economic losses of up to $3.6 billion if containment fails, but only 10% of the $319 million budget requested for the response had been secured as of late May .